Member Info for BIGBONE

Just tried buying in through Barx but not listed . DGQ.PL ?

Merry Xmas all. Peace, good health and goodwill to all.(and the green box lot).!

Vlad and team keep up the exceptional work not all heros wear capes!

I'm half expecting an RNS on 23rd to stop the sp tanking by organised shorters , that said HEMO are coming up to a news rich period and possible Stella re rate.

Seller or dark pool supply!?

Pumpky.

There is a unit there called the teenage cancer trust ( with amazing staff.) I wish and hope that Hemogenyx science will go along way to helping those that need it most there.

Also can't for get Ronald Mcdonald house and the support they give families. Amazing both.

It's simple to me the big boys want our shares cheap , auto trades , algorithms it's all here to hover up .

To Not posting take a trip to Birmingham Children's Hospital then you will understand the need for this company to succeed.

Won't be able to read your reply as green boxed and will stay that way.

That's quite possible!

Level of manipulation unbelievable.

But the adjustment has started back to a reasonable SP.

High Volume: Today's trading volume (127,480 shares) is much higher than the average. High volume on a down day can sometimes signal a "capitulation" event, where all motivated sellers have exited the market, potentially setting the stage for a short-term bounce or stabilization.. Unless fear and fud are spread tomorrow could see a more stable day , few good buys at the end of today.

London stock exchange take a stand on abuse of AIM . Least it's a start article in the Times.

I see they appeared on ADVFN. With multiple tags reported to the FCA also.

Things to look forward to further news and updates from Hemogenyx Pharmaceuticals are expected before the end of December 2025, specifically regarding ongoing clinical trials and commercialization efforts.

The company outlined several key priorities for the remainder of 2025 in its half-year report, which serve as potential subjects for future announcements.

Expected Updates

Dose Escalation: A primary focus is on DSMB (Data and Safety Monitoring Board) review of data from the first three patients in the Phase 1 trial for HG-CT-1 therapy. Subject to DSMB approval, the company will advance into the next dose cohort, which would be a material news event.

Pediatric Enrolment: Having received regulatory clearance in October 2025 to initiate enrolment of pediatric patients in the trial, the company is working to operationalize this expansion, and an announcement related to the first patient enrollment would be expected.

Commercialization in Estonia: The company is finalizing discussions with Cellin Technologies to establish a framework for supplying its HG-CT-1 therapy under the Estonian hospital exemption pathway, potentially generating early revenue. An agreement or supply update could be announced.

Manufacturing Scale-up: Progress on the technology transfer with Made Scientific to improve manufacturing efficiency and scalability is another stated objective for this period.

GLA DYOR.

Nice climb hope long may it continue.

Has lse been infiltrated lots of positive post removed ,

Sorry fact checked i did use Google AI .

Should have gone to the source !

Can see why NP gets from.

Vlad is not attending it is an abstract. But who knows he may be there.

Hemogenyx Pharmaceuticals will have an abstract presented at the 67th American Society of Hematology (ASH) Annual Meeting, which takes place on December 6-9, 2025, in Orlando, Florida.

The presentation will be based on an abstract submitted to the conference. The official program and the abstracts were made available online to registered attendees in November 2025, allowing participants to plan their schedules.

ASH Annual Meeting & Exposition website.

Lostapound it's on the ASH website site as of yesterday.

GLA

Almost a sea of blue , nice steady rise back before Vlad drops the RNS .

I wonder what Vlad makes of the market manipulation .

Just gone vertical something a foot .